In:
Tumori Journal, SAGE Publications, Vol. 108, No. 5 ( 2022-10), p. 407-419
Kurzfassung:
People at high risk of morbidity and mortality from coronavirus disease 2019 (COVID-19), including patients dealing with malignancies and patients on immunosuppressive anticancer therapies, need to be followed carefully as the pandemic continues. Challenges in continuing cancer management and patient monitoring are of concern given the importance of timing in cancer therapy. Alternative treatment decisions and priorities are also important considerations. The efficacy and safety of various cancer treatments in patients with COVID-19 are other important considerations. In this systematic review, we summarize the potential risks and benefits of cancer treatments applied to patients with COVID-19 and malignant tumors. Using the PubMed and Scopus databases, we reviewed studies involving cancer therapy and COVID-19 to address the recent discoveries and related challenges of cancer therapy in patients with COVID-19 and cancer.
Materialart:
Online-Ressource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/03008916211063939
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2022
ZDB Id:
280962-X
ZDB Id:
2267832-3
